表紙
市場調査レポート

V503(ヒトパピローマウイルス(HPV)予防ワクチン)- 予測と市場分析

V503 (Prophylactic Human Papillomavirus Vaccines) - Forecast and Market Analysis to 2022

発行 GlobalData 商品コード 307136
出版日 ページ情報 英文 69 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
V503(ヒトパピローマウイルス(HPV)予防ワクチン)- 予測と市場分析 V503 (Prophylactic Human Papillomavirus Vaccines) - Forecast and Market Analysis to 2022
出版日: 2014年03月31日 ページ情報: 英文 69 Pages
概要

ヒトパピローマウイルス(HPV)に対する最初の予防接種ワクチンは、2006年に使用されるようになりました。世界のHPVワクチン市場は今では確立されていますが、従来の目標母集団である若年女子に対するワクチン接種率は依然として低調です。当初、HPVワクチンは子宮頸癌の予防ワクチンとして開発され、上市されました。近年では、その他の癌に対するHPVの役割が次第に認められるようになり、一部の国では定期的なワクチン接種勧奨に男性も含めるなど、幅広い層にワクチン接種が行われるようになってきています。

当レポートでは、HPVワクチンであるV503について調査分析し、疾患の概要と治療ガイドライン、競合情勢、製品情報、主要国の売上予測などについて、体系的な情報を提供しています。

第1章 目次

第2章 イントロダクション

第3章 疾患の概要

  • 病因・病態生理
    • 病因
    • 病態生理
  • 症状

第4章 ワクチン接種勧奨と接種率

  • 接種勧奨の概要

第5章 競合評価

  • 概要
  • 戦略的競合企業の評価

第6章 アンメットニーズと機会

  • 概要
  • 複数のHPV型に対する予防
  • ワクチン接種率
  • ワクチンの安全性に対する認識
  • HPVワクチンの認識
  • HPVワクチンの価格
  • 特定層で流行しているHPV型の接種率
  • ワクチン接種の順守率
  • HPV感染に対する終生免疫は獲得できず
  • 子宮頸癌検査に対する継続的なニーズ

第7章 パイプライン評価

  • 概要
  • 臨床開発中の有望なワクチン

第8章 V503

  • 概要
  • 効能
  • 安全性
  • 投与・処方
  • 潜在的な臨床の位置付け
  • 潜在的な商業の位置付け
  • 価格と償還
  • SWOT分析
  • 予測

第9章 付録

図表

目次
Product Code: GDHC388DFR

The first prophylactic vaccine for immunization against human papillomavirus (HPV) became available in 2006. The global HPV vaccines market is now well established, yet vaccine coverage rates amongst the traditional target population of adolescent girls remain persistently low. Initially HPV vaccines were developed and marketed solely to protect against cervical cancer. In recent years the role of HPV in other cancers has been increasingly recognized which has facilitated a shift towards vaccinating a wider population, most significant has been the inclusion of males in routine vaccine recommendations in some countries. The current HPV vaccines market is dominated by one major player, Merck's Gardasil, with GlaxoSmithKline's (GSK's) HPV vaccine Cervarix providing the only competition. The introduction of Merck's nine-valent vaccine (V503) is set to change the future landscape of the HPV vaccines sector.

Merck is developing V503, a nine-valent HPV vaccine; like Gardasil, this vaccine is being developed in partnership with CSL, from which Merck is licensing VLP technology. Both V503 and Merck's current vaccine Gardasil have a similar mechanism of action, consisting of VLPs combined with aluminum salt adjuvant, delivered as an IM injection over a three-dose course. Merck has recently registered a Phase III trial to assess the immunogenicity of V503 given over a two-dose course (Merck, NCT01984697).

Scope

  • Overview of HPV, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on V503 including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for V503 for the top eight countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Canada and Australia

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for HPV
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of V503 performance
  • Obtain sales forecast for V503 from 2012-2022 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Canada and Australia)

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms

4. Vaccination Recommendations and Coverage Rates

  • 4.1. Vaccination Recommendations Overview

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment

6. Unmet Need and Opportunity

  • 6.1. Overview
  • 6.2. Protection against Multiple HPV Types
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Vaccine Coverage Rates
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Perception of Vaccine Safety
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Awareness of HPV Vaccination
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity
  • 6.6. Affordability of HPV Vaccines
    • 6.6.1. Unmet Need
    • 6.6.2. Gap Analysis
    • 6.6.3. Opportunity
  • 6.7. Coverage of HPV Types Prevalent in Certain Populations
    • 6.7.1. Unmet Need
    • 6.7.2. Gap Analysis
    • 6.7.3. Opportunity
  • 6.8. Vaccine Compliance Rates
    • 6.8.1. Unmet Need
    • 6.8.2. Gap Analysis
    • 6.8.3. Opportunity
  • 6.9. Lifelong Protection from HPV Infection Not Established
    • 6.9.1. Unmet Need
    • 6.9.2. Gap Analysis
    • 6.9.3. Opportunity
  • 6.10. Ongoing Need for Cervical Cancer Screening
    • 6.10.1. Unmet Need
    • 6.10.2. Gap Analysis
    • 6.10.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Vaccines in Clinical Development

8. V503

  • 8.1. Overview
  • 8.2. Immunogenicity
  • 8.3. Safety
  • 8.4. Dosing and Formulation
  • 8.5. Potential Clinical Positioning
  • 8.6. Potential Commercial Positioning
  • 8.7. Pricing and Reimbursement
  • 8.8. SWOT Analysis
  • 8.9. Forecast

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Vaccine Coverage
    • 9.4.2. Vaccine Approval versus Routine Schedule Inclusion
    • 9.4.3. General Pricing Assumptions
    • 9.4.4. Individual Drug Assumptions
    • 9.4.5. Pricing of Pipeline Agents
  • 9.5. Physicians and Specialists Included in this Study
  • 9.6. About the Author(s)
    • 9.6.1. Author(s)
    • 9.6.2. Therapy Area Director
    • 9.6.3. Global Head of Healthcare
  • 9.7. About GlobalData
  • 9.8. Disclaimer

List of Tables

  • Table 1: Histological Progression Towards Cervical Cancer
  • Table 2: Diseases Associated with HPV Infection and Their Associated Symptoms
  • Table 3: HPV Vaccine Recommendation Agencies by Country
  • Table 4: Targeted Group(s) for Recommended Immunization and Most-Administered HPV Vaccine by Country in the Global Markets, 2014
  • Table 5: Marketed Vaccines for HPV, 2014
  • Table 6: Overall Unmet Needs - Current and Future Level of Attainment
  • Table 7: HPV Vaccines - Phase Pipeline, 2014
  • Table 8: Product Profile - V503
  • Table 9: V503 SWOT Analysis, 2013
  • Table 10: Global Sales Forecasts ($m) for V503, 2012-2022
  • Table 11: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: Competitive Assessment of Late-Stage Pipeline Agents in HPV Vaccines, 2012-2022
Back to Top